Registered Members Login:
   
Forgotten Your Details? Click Here To Recover +
Welcome To The ShareCafe Community - Talk Shares And Take Stock With Smart Investors - New Here? Click To Register >

4723 Pages (Click to Jump) V  « < 391 392 393 394 395 396 397 > »    
 
  
Reply to this topic

CUV, CLINUVEL PHARMACEUTICALS LIMITED
NewToCli
post Posted: Mar 6 2019, 02:30 AM
  Quote Post


Posts: 735
Thanks: 1397


Ur9 ticking up every minute .. 17.33 eur ATH


Said 'Thanks' for this post: gerritbakker57  mrdax  
 
PunkassDerm
post Posted: Mar 5 2019, 11:41 PM
  Quote Post


Posts: 519
Thanks: 1396


Awesome! ...as long as it "pays off in the end," for all

Rich Bosses 2019: Meet Australia's 10 wealthiest executives
James Thomson
Mar 5, 2019 — 11.00pm

Canny investors have long believed that backing executives with skin in the game is a winning strategy. The 2019 Rich Bosses list is more proof of that strategy.
The list ranks managers and executive directors from companies in the ASX 300 according to value of the business they work in.
The full list, which was last year topped by Seven Group executive chairman Kerry Stokes, will be published in Boss magazine in Friday's edition of The Australian Financial Review.

.........

Clinuvel Pharmaceutical

Another strong performer was Clinuvel Pharmaceuticals, which produced a total shareholder return of 151 per cent in the year in question.
The biotechnology firm focused on developing treatments for a range of severe genetic and skin disorders; it's flagship drug Scenesse is in trials in the United States and Europe.
The company's chief executive, Philippe Wolgen, is a former life sciences equity analyst with deep experience in European financial markets; he has a stake worth $72 million and had total remuneration of $2.3 million in the 2018 financial year.


Said 'Thanks' for this post: NewToCli  johnnytech  
 
NewToCli
post Posted: Mar 5 2019, 11:30 PM
  Quote Post


Posts: 735
Thanks: 1397


In Reply To: odi01's post @ Mar 5 2019, 10:25 PM

Need to subscribe to read it ... they mention PW? smile.gif

 
odi01
post Posted: Mar 5 2019, 10:25 PM
  Quote Post


Posts: 632
Thanks: 1452


https://www.afr.com/business/rich-bosses-20...20190304-h1bz1a


Said 'Thanks' for this post: PunkassDerm  
 
seeva222
post Posted: Mar 5 2019, 06:45 AM
  Quote Post


Posts: 1,358
Thanks: 1452


In Reply To: NewToCli's post @ Mar 5 2019, 06:14 AM

This is the big Kahuna. Anti-oxident, anti-inflammatory properties + OTC will get Walnut a real footy team.


Said 'Thanks' for this post: Doogieson  NewToCli  
 
NewToCli
post Posted: Mar 5 2019, 06:14 AM
  Quote Post


Posts: 735
Thanks: 1397


In Reply To: PunkassDerm's post @ Mar 5 2019, 04:11 AM

The anti oxidant effect of Scenesse might even be the bigger benefit for the EPP sufferers than the pigmentation of the skin.

Regarding asx200 and the investor presentation:

Let’s remember to read between the lines with the cuv communication:

August 21, 2018; Clinuvel Investor Presentation
September 07, 2018: ASX300 quarterly rebalancing

Quite a good hint cuv might well be including in the asx200


Said 'Thanks' for this post: sharelooker  Farleap11  macgyver  waz  ajshare  
 


PunkassDerm
post Posted: Mar 5 2019, 04:11 AM
  Quote Post


Posts: 519
Thanks: 1396


In Reply To: royco's post @ Mar 5 2019, 04:08 AM

I agreed wholeheartedly. The free radial protection alone is anti-aging/anti-cancer.

I think shareholders of note should have access to 4x yearly implants, sign me up.

Frilly Frilly


Said 'Thanks' for this post: johnnytech  waz  Doogieson  
 
royco
post Posted: Mar 5 2019, 04:08 AM
  Quote Post


Posts: 2,910
Thanks: 4509


In fact some of those 2010 swiss patients will know by now, first hand.
The question is if someone is speaking out, if someone is listening and taking note.
Best would be a scientist/medical practitioner and patient in 1 and the same person.
I can think of some already.




--------------------
Ἀρτεμίσιον

Said 'Thanks' for this post: PunkassDerm  
 
royco
post Posted: Mar 5 2019, 04:04 AM
  Quote Post


Posts: 2,910
Thanks: 4509


Cuv is gaining expertise with every implant, every day and every patient treated in the eu.
The data gathered is unique, vaste and hopefully wide enough to also capture scientific knowledge on long term effects of scenesse in otherwise healthy epp patients.
I presume that if any more protective effects exist they will become apparent when comparing this subpopulation to the entire population..
EPP patients on scenesse should have an overall better health, qol and eventually higher life expectancy than the population in general.
Time (years)will tell, cuv will know first.



--------------------
Ἀρτεμίσιον

Said 'Thanks' for this post: PunkassDerm  waz  
 
Desert Rat
post Posted: Mar 5 2019, 03:46 AM
  Quote Post


Posts: 76
Thanks: 225


In Reply To: Frogster's post @ Mar 4 2019, 02:29 PM

Agree with you, Frogster. CUV has consistently missed opportunities to hire scientifically-relevant and clinically-relevant expertise. To wit, Clinuvel has no one in the company with established scientific expertise in melanotropins and no one with established clinical expertise in dermatology. Think about that for a moment: a company marketing a first-in-class melanotropic peptide for a true orphan dermatologic/hematologic disease, but with no established expert personnel in either area. By established, I mean personnel who have published relevant and recent peer-reviewed papers in melanotropins and light-sensitive dermatoses. Those types of personnel are available, even to simply constitute a formal scientific advisory panel, which is typically done in almost all technological companies. But I doubt that PW would want to have to deal with them on a daily basis.


Said 'Thanks' for this post: Frogster  
 
 


4723 Pages (Click to Jump) V  « < 391 392 393 394 395 396 397 > » 

Back To Top Of Page
Reply to this topic


You agree through the use of ShareCafe, that you understand and accept the TERMS OF USE.


TERMS OF USE  -  CONTACT ADMIN  -  ADVERTISING